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Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory and destructive joint disorder that affects tens of millions
of people worldwide. Normal healthy joints maintain a balance between the synthesis of extracellular matrix (ECM)
molecules and the proteolytic degradation of damaged ones. In the case of RA, this balance is shifted toward matrix
destruction due to increased production of cleavage enzymes and the presence of (autoimmune) immunoglobulins
resulting from an inflammation induced immune response. Herein we demonstrate that a polyclonal antibody against the
proteoglycan biglycan (BG) causes tissue destruction that may be analogous to that of RA affected tissues. The effect of the
antibody is more potent than harsh chemical and/or enzymatic treatments designed to mimic arthritis-like fibril de-
polymerization. In RA cases, the immune response to inflammation causes synovial fibroblasts, monocytes and
macrophages to produce cytokines and secrete matrix remodeling enzymes, whereas B cells are stimulated to produce
immunoglobulins. The specific antigen that causes the RA immune response has not yet been identified, although possible
candidates have been proposed, including collagen types I and II, and proteoglycans (PG’s) such as biglycan. We speculate
that the initiation of RA associated tissue destruction in vivo may involve a similar non-enzymatic decomposition of collagen
fibrils via the immunoglobulins themselves that we observe here ex vivo.
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Introduction
The major parts of the joint which are affected most
prominently in RA, are articular cartilage and the synovium.
Collagen type II fibrils are major structural elements of the
cartilage ECM and the cartilage-like notochord of cartilaginous
fishes. They form 67 nm periodic fibrils and fibers, with the
participation of proteoglycans (PG’s), which bind collagen by their
core protein and regulate collagen fiber diameter through their
anionic glycosaminoglycan (AGAG) chains. These collagen-PG
interactions are also essential for fiber/fibril stability and
determine a number of their mechanical properties [1–5]. In
cartilage, collagen type II also aggregates with other collagen types
(I, V, IX and XI) [6] and PG’s to form complex fibrillar
meshworks, in contrast to the simple arrangement in notochord.
Although the type II collagen fibrils themselves are indistinguish-
able between the two tissues [7–9]. Aggrecan in complex with
hyaluronan is embedded within these meshworks and accumulates
a substantial amount of water (70% of cartilage mass) by their
highly negative charge.
The synovium, or synovial membrane, is a thin sheet of
vascularized mesenchymal tissue that surrounds the joint cavity
and produces synovial fluid, which is responsible for joint
lubrication and chondrocyte nutrition, since avascular cartilage
is impermeable to oxygen and nutrients in mature joints [10]. The
ECM of synovium is composed of collagen fibrils (types I, III, and
V, type II is not present) of relatively small diameter (30 nm) with
67 nm periodicity and thin filaments (10 nm) of collagen type VI
(with 100 nm periodicity), which are integrated with hyaluronan,
fibronectin, and fibrillin, providing tissue permeability and
structural integrity [10].
PG’s, such as the small leucine rich repeat proteins (sLRRP’s)
decorin and biglycan, are essential for stabilization of fibril-bundle
structures [11] and for conveying compression resistance together
with hyaluronan and aggrecan. Here we report that biglycan
bound type II collagen fibril-bundles (or fibers, also known as thick
fibrils of 30–50 nm diameter) are decomposed into discrete fibrils
(also known as thin-fibrils of ,10–15 nm diameter) through the
action of anti-biglycan antibody, even in the absence of cells,
enzymes, other antibodies and in the presence of enzyme
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32241inhibitors. This antibody induced process results in the breakdown
of notochord and the appearance of thin-fibrils in cartilage
samples.
Results and Discussion
Extracellular matrix degradation during RA
Part of the RA inflammatory response is release of proteases,
such as matrix metalloproteinases (MMPs) and ‘‘a disintegrin and
metalloproteinases with thrombospondin motifs’’ (ADAMTSs),
which digest the ECM of the synovium and cartilage. The major
targets in cartilage are collagen type II, PG’s (decorin, biglycan)
and aggrecan; their remnants were detected in body fluids of RA
patients [12–15]. As a result of Polgar proteolysis, the superficial
layer of cartilage is destroyed [16] and its structure and
biomechanical properties are altered. The loss of PGs and
aggrecan leads to a decrease of water molecules in cartilage and
therefore resistance to compression, but it may also affect the
stability of collagen fibrils and makes them more vulnerable to
MMPs.
Initial ECM degradation, however, may occur in the absence of
proteases. Severe mechanical loads as well as changes in pH may
cause cartilage fibrillation [17,18]. Depleted PG content is
observed in the articular cartilage of RA patients accompanied
with fibrillar fragmentation [19]. Whilst elevated levels of biglycan
antibodies have been detected in serum and synovial fluid of RA
patients [20] and they are considered to be early markers of this
disease. However the exact role of these antibodies in initiation
and development of the drastic changes RA causes to cartilage has
remained unclear as does the specific mechanism of tissue
destruction. Here we present evidence of the potent effect of an
antibody to biglycan on cartilage-like (lamprey notochord) and
articular cartilage tissues at physiological pH and in the absence of
cell associated or free enzymes. In the presence of this antibody,
type II collagen thick-fibrils are quickly decomposed into much
smaller species inducing irreversible damage to the tissues, as
visualized by electron microscopy, atomic force microscopy and
X-ray diffraction (FIGS. 1, 2, 3, 4, and 5). Apart from the possible
significance of this observation to RA, we are unaware of any
previous reports of autoimmune associated antibodies being
directly responsible for inducing such destruction of vertebrate
and mammalian connective tissues.
Antibody induced tissue decomposition
Native fibrils of lamprey notochord do not show any detectable
difference between its collagen type II fibers and those seen from
the tissues of mammals [21] (FIG. 1). They have the same
diameter of about 35 nm and typical positive staining pattern,
although there are some differences in cellular and proteoglycan
content, as well as tissue architecture. Lamprey notochord appears
to have a very specific cell distribution (layered, outside of the
bands of extracelluar material), whereas cartilage cells are
embedded in a collagen meshwork and can be seen throughout
the whole tissue. The PG content of lamprey notochord is fairly
simple containing only biglycan type I and II (which are very close
in sequence to the bovine or human biglycans, and hence
structurally related to decorin and fibromodulin), in contrast to the
mammalian cartilage which has several types of PG’s and
glycoproteins present [22,23].
TEM images of lamprey tissues treated with the biglycan
antibodies showed (FIGS. 1–2) a striking difference from the native
fibers: 1) much thinner collagen fibers about 11 nm in diameter
are present through-out the samples or more accurately, there was
a notable absence of native thick-fibrils (Tables S1 and S2) and 2)
the ECM became significantly less well ordered. The antibody
treated notochord (FIG. 1B) after treatment was very delicate and
easy to deform, unable to withstand even minimal strain (,5%)
without its destruction. Mammalian tissues were not affected so
dramatically (FIGS. 1 and 4), but they also showed the appearance
of thin fibrils and disrupted fibers in the presence of the antibody,
not present in the control (pre-treated) sections in such quantities
(FIG. 1). The difference in the relative effect on the two animal
tissues (cartilage vs. notochord) is presumably due to the
mammalian cartilage possessing a wider repertoire of sLRRP’s
that are either completely or partially resistant to the effects of the
anti-biglycan antibody (see below). Lamprey notochord with only
biglycan is therefore more susceptible to any putative effects of its
antibody. Regardless of the difference in scale of effect, the same
unexpected observation was made between the tissues: Significant
and rapid non-enzymatic decomposition of collagen fibrils occurs
in the presence of the anti-biglycan antibody. Large BG core
protein sized structures observed in TEM of incubating solution
with presence of gold particles. Biochemical analysis shows
significantly elevated levels of BG in this solution relative to non-
ab containing controls (see SI methods S1, Tables S3 and S4, and
FIG. 5).
We suggest, that anti-biglycan antibodies attach to biglycan
core-proteins on the surface of thick-fibrils and that this interaction
disrupts the bonding between the core-protein and the collagen
molecules comprising the fibrils. Even though GAG bridges
remain intact, the loosening of the biglycan core-protein – collagen
interaction ‘unties the string’ that holds the thick-fibrils together
(FIG. 3). This further implies that ‘thick-fibrils’ are in fact bundles
of thin fibrils (i.e. the ‘fibril bundles’ discussed throughout this
study). Whereas a ‘thin-fibril’ [24] is an irreducible collagen fibril
(without enzymatic digestion or mechanical force) formed from
closely packed collagen molecules and held together through
collagen-collagen interactions such as lysine-hydroxylysine bonds.
Controls
In order to test the hypothesis that disruption of the biglycan
core-protein – collagen interaction accounts for the fibril-
debundling, lamprey notochord samples were treated with
Guanidine hydrochloride and ABC lyase respectively as a positive
control. Guanidine hydrochloride causes protein denaturation,
therefore its action would mimic the hypothesized action of the
biglycan antibody, albeit in a more caustic and less specific
manner. TEM images of Guanidine treated notochord and
cartilage illustrated the same type of degradation of collagen
fibrils, although the incubation time had to be much longer (24 h
instead of 1 h for the antibody) to achieve a similar degree of
decomposition. In contrast, ABC lyase removes the AGAG chain
from the protein core and should produce the similar results albeit
via a different structural mechanism. Thin fibrils in both
notochord and articular cartilage samples were seen in TEM
images after this treatment, although damage was relatively mild
in comparison to the antibody-mediated decomposition. In
addition to these chemical methods of tissue degradation,
mechanical degradation was also examined. Friction was applied
to native lamprey notochord tissues and the results of this damage
were analyzed by TEM and compared with the other experiments.
Mechanical impact, used for this study, may correspond to
damage of the articular cartilage due to trauma or normal wear.
The presence of thin fibrils were observed (absence of regular 30–
50 nm fibrils) in certain areas, which had higher load, although
some parts of tissue still had normal architecture in comparison to
undamaged, non-treated control samples. Finally, significant tissue
degradation (and biglycan release) was observed in the presence of
Anti-Biglycan Decomposes Collagen Fibrils
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such as anti-collagen (see SI methods S1).
Notochord structure: differences in scale of the effect of
anti-biglycan on lamprey vs. mammalian tissues
Lamprey notochord is a cartilage-like tissue that spans the
length of the chordate back, located beneath and parallel to the
central nervous system between the brain and tail. Although it is
the main axial skeleton at the embryonic stage, the notochord is
replaced by the vertebral column in most vertebrates. However, in
some chordates it remains into adulthood (e.g., lamprey, lungfish,
sturgeon, and some sharks). The mature notochord contains a soft
cellular inner part, surrounded by protective fibrous sheath,
composed of three layers: inner basal lamina, thick collagenous
(cartilage-like) layer, and elastic filamentous membrane [25]. The
composition of collagenous part of lamprey notochord is rather
simple compared to articular cartilage, which makes it very
convenient to study. It has two main collagen type II fiber
orientations: circular (perpendicular to the main body axis) and
longitudinal (parallel to the main axis of the body). Longitudinally
organized fibers are located at the outer layer and are the most
prevalent. The fibrillar architecture is supported by the lamprey
biglycan. Although the organization of articular cartilage and
lamprey notochord seem to be different, the structure of collagen
type II fibrils in both of them is indistinguishable [25] and their
sequence is highly homologous.
Variations in the different level of damage (thin/normal
collagen type II fibrils), obvious in TEM images of mammalian
and lamprey tissues, can be explained by differences in the
molecular composition of these tissues that in turn influences the
tissue architecture. Lamprey notochord contains primarily colla-
gen type II and biglycan. Human and bovine articular cartilage
contain biglycan, fibromodulin, decorin, and other ECM mole-
cules, which regulate fibrillogenesis, fiber diameter, support fibers,
Figure 1. Decomposition of collagen type II fibrils in lamprey notochord viewed with TEM (A–D) and bovine articular cartilage (E
and F). A) Native (prior to fixing) type II collagen fibrils, incubated in TBS as control for fibril samples shown in B–D. Average fibril size is around
35 nm. B) Collagen type II fibrils following short incubation with anti-biglycan antibody. Fibril diameter is 10–15 nm. C) Collagen type II fibrils
following incubation in GHCl. Although severely disrupted, the fibril decomposition appears less complete than that of the antibody incubation (B).
D) Collagen type II sample following mechanical disruption. Disruption of native fibril structure is highly localized, with large sections still intact. E)
Native bovine articular cartilage (prior to fixing and staining for TEM). F) Bovine articular cartilage post 1 hour treatment with anti-biglycan. Black
arrows point to thin-fibrils, white arrows point to normal sized thick-fibrils.
doi:10.1371/journal.pone.0032241.g001
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meniscus contain more biglycan than decorin and the ratio
changes from zone to zone. The superficial zone contains about
32% of decorin and 38% of biglycan of all PG content, the inner
deep zone contains about 23% of decorin and 53% of biglycan of
all PGs, and middle zone has 28% of decorin and 52% of biglycan
of all PG’s [26]. As a result these tissues can be expected to be
more resistant to short duration (1–2 hours) antibody treatment.
Due to the presence of decorin, which seems to be stable in the
presence of the antibody (this antibody has higher affinity to
biglycan, than decorin). But longer exposure of cartilage tissues to
biglycan antibodies has a stronger effect on cartilage collagen fiber
disassociation, presumably because the antibodies need more time
to penetrate to deeper layers where biglycan is predominant.
Antibody concentration and effect
Although our observations are ex vivo, it is worth noting that
human autoimmune disease antibody concentration levels have
been reported in body fluids at levels similar to or higher than we
have applied in our experiments [27–29], although we also
observed this effect in lower starting concentrations (see SI
methods S1). What is more, the observed fibril decomposition
permeated whole tissue samples immersed in the antibody
containing vials. The concentration of the antibody in the tissue
interior must have been substantially lower than in the
surrounding solution, and yet, still caused tissue degradation.
That the effect was observed in so short a period of time (in
notochord) is also significant.
Given that the concentration of the antibody used may be
physiologically relevant, the nature of its disruptive affect may be
the same in vivo as our ex vivo experiments, be that through
competitive bond disruption or steric repulsion or both. However,
as FIG. 3 indicates, it is quite unlikely that more than one antibody
molecule may locate to one biglycan core proteins epitope, making
the steric repulsion consideration less likely. Especially in light of
published studies that indicate sLRRP’s conformations are not
easily given to significant changes to their arching structure but do
seem to be sensitive to the environments effect on their inner-core
to collagen fibril hydrogen bonding network [1,4]. The fact that
we observed some sensitivity of tissues to certain salts in buffer
systems (see SI methods S1and PBS) and that simple denaturing
conditions (see guanidine hydrochloride GHCL results) were less
effective than the application of the antibody may be considered
collaborating evidence in favor of the interaction interference
effect of the anti-biglycan antibody. It has long been known that
pH causes collagen fiber bundles to disassociate into smaller
species [30,31], the latter reference speculating that the sLRRP
proteoglycans are sensitive to both salt and pH conditions. That
we observed this affect at natural pH in a phosphate based buffer
system would seem to collaborate these prior considerations. That
we did not observe fibril-bundle degradation in TBS controls and
poorer destruction of fibril bundles in TBS via GHCL or enzyme
catalysis, suggests a novel effect of the anti-biglycan antibody
against type II collagen fiber bundles. That the thin-fibrils were
not further degraded but remained indefinitely stable rules out the
possibility of a general or collagen specific proteinase. The
significantly elevated levels of biglycan detected in the anti-
biglycan solution in which the tissue were incubated relative to
controls without the anti-antibody, supports the hypothesis that
anti-biglycan causes the disassociation of biglycan from thick-
fibrils.
Figure 2. Type II collagen fibrils decomposed into their basic aggregates (viewed via X-ray diffraction and TEM). Some parts of the
antibody treated samples maintain a loose alignment of the thin-fibrils allowing them to be analyzed with small angle X-ray diffraction (A), and insert
B. An 11 and 4.5 nm packing function are apparent, which appear to correspond to the approximate diameter of the thin-fibrils (insert of C) and
microfibrils (D). Native thick fibrils are shown in C as a comparison to the decomposition product (thin-fibrils).
doi:10.1371/journal.pone.0032241.g002
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interaction domain
Collagen fibrils are assembled in such way that the MMP
collagenase cleavage-site is protected by the C-telopeptide in
folded conformation [32–34]. This folded C-telopeptide corre-
sponds to the X3 ridge in type I collagen, and appears to have an
analogous structure in type II collagen as observed from AFM and
X-ray diffraction data [32,33]. The C-telopeptide is usually cross-
linked covalently with neighboring collagen molecules, that helps
makes its conformation very stable. In order to gain access to the
MMP cleavage-site, other proteases have to cleave the C-
telopeptide first. This process is very slow with MMP1 alone due
to a very low number of available cleavage sites (presumably at the
fibril tips were collagen packing is looser). Our results show that
the biglycan antibody can induce the process of collagen fiber
decomposition in cartilage-like tissues. Even a short, one-hour
exposure of lamprey notochord to biglycan antibody completely
altered the structure of the collagen matrix. In fact there were only
few areas in the treated notochord that were not altered
dramatically (fibrils disassociated, but stayed close and parallel to
each other) and therefore were capable of yielding diffraction
patterns (FIG. 2). Even these ‘less affected’ tissue area’s showed
significant structural changes and most importantly, almost
uniform fibrillar decomposition. Our preliminarily data (not
shown) of enzymatic digestion of antibody incubated notochord
showed that the tissue was decomposed at least a factor of 2 times
faster than the controls (at 4uC, compared with MMP1, trypsin
and pepsin), indicating that previously exposed cleavage sites were
becoming exposed due to the action of the antibody on BG (i.e
because fibril-bundles are being disrupted, yielding their constit-
uent thin-fibrils and biglycan, see FIGS. 3 and 5).
A speculative molecular based mechanism for RA
associated tissue destruction
The observed tissue destruction in lamprey notochord and
analogous fibrillar decomposition in articular cartilage as a
response to anti-biglycan treatment, may have significance to
human health and aging. Elevated levels of anti-biglycan
antibodies are detected in the body fluids of arthritis patients
[20], and are considered early markers of this disease, but their
specific role has not previously been clarified. The presence of
thinner fibers and high concentration of collagen cleavage
products are also connected to RA events [35]. Our results from
biglycan antibody treatment – cartilage/notochord collagen
interactions visualized by TEM and supported by X-ray
diffraction based evidence of collagen fibril architecture and
collagenolysis [32,33,36,37] can be used to propose a mechanism
of collagen matrix degradation by MMPs, initiated by autoim-
Figure 3. Model of antibody action on type II collagen fibrils. Coordinate models of the biglycan-type II collagen fibril complex based on the
decoron-type I collagen fibril structures published recently (1) are shown with a model Fab (green) unit attaching to the biglycan (blue) epitope
(colored red, A and ‘top’ view B). Because the epitope is located within a solvent filled channel of the collagen fibril [33], there is room for loops of the
fab to dock with it, but its close proximately to the fibril-PG hydrogen bonding network located between the collagen fibril surface and the concave
side of the PG-core proteins structure (1) may disrupt the positive interactions and dislodge the core protein from the fibril. Leading to the
debundling of thick-fibrils into their constitutive thin-fibrils (C).
doi:10.1371/journal.pone.0032241.g003
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cartilage PG’s strongly depends on their specific conformation
[38]. Thus, even small changes may be enough to disrupt the
connection between biglycan and collagen molecules. Recent work
to define the nature of the interaction between the biglycan
homologue, decorin, and the type I collagen fibril suggests how
this might occur; a disruption to the hydrogen bonding network of
the PG-core protein-collagen fibril interface [4] in the region of
the anti-biglycan antibody epitope (see methods). Therefore we
speculate that the process of RA tissue destruction could begin
here or be one of the early factors leading to the pathological
cascade of RA:
1. Antibodies against biglycan (and perhaps other sLRRP protein
cores, although biglycan appears to be the most vulnerable as
decorin appears unaffected despite its close homology) binds to
the PG-core protein and disrupts the hydrogen-bonding
network on the interior of the concave surface that binds to
the collagen fibril.
2. Biglycan core-protein dissociates from the collagen fibrils and
the fibril bundle decomposes into thin-fibrils.
3. Having dissociated from the fibril-bundle, the collagen type II
thin-fibrils have a higher exposure of catalytic sites (increased
surface area to volume ratio) and become vulnerable to
collagenase and gelatinase binding, unwinding and cleavage
(see above and refs. [33,37]). Therefore, this altered collagen
matrix is more fragile and readily digested by proteases.
4. We further speculate, that with the breakdown of these
molecular aggregates, a host of normally hidden or low-
concentration epitopes, such as PG breakdown products,
collagen peptides and so on, would become present in higher
concentrations than before. Theoretically, this could initiate a
immunological cascade that leads to further tissue autoimmune
activity and a worsening of the disease.
Lamprey notochord has a rather simple composition in
comparison to mammalian cartilage, but this helps make it both
an appealing and suitable model of mammalian systems for initial
investigation of normal and pathological processes in cartilage at
the fibrillar level. The examined interaction of anti-biglycan
antibodies with the notochord ECM can serve as a model for the
mechanism of rheumatoid arthritis and has potential as a simplistic
Figure 4. TEM images of human articular cartilage preparations. A) Section of native human articular cartilage, incubated in TBS, that has
collagen type II fibrils of regular 30–50 nm diameter (control for samples B–D). B) Section of human articular cartilage treated with ABC lyase for 24 h
with some thin fibrils of collagen type II. C) Section of human articular cartilage treated with Guanidine hydrochloride for 24 h with presence of thin
10–15 nm fibrils and normal thick fibrils (fibril bundles). D) Section of human articular cartilage, treated with anti-biglycan antibody for 24 h, shows
some collagen type II thin fibrils as well as fibrils of regular 30–50 nm diameter. Arrows point to decomposing fibrils.
doi:10.1371/journal.pone.0032241.g004
Anti-Biglycan Decomposes Collagen Fibrils
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32241RA model system. The visualization of antibody-treated tissues
under different conditions inspires a speculative model of tissue
destruction similar to that seen in autoimmune-induced rheuma-
toid arthritis, characterized by collagen matrix decomposition due
to PG disruption by the anti-biglycan antibody. This proposed
model highlights the crucial position of the biglycan antibody in
the development of rheumatoid arthritis and our associated
observations provide the first indication of what its role is beyond
being a marker of this common and widespread disease.
Materials and Methods
Materials
Adult Sea lampreys were donated by Ludington Biological
Station of the U.S. Fish and Wildlife Service and J. Ellen Marsden
of the University of Vermont. Human and bovine articular
cartilage, stored under physiological conditions, were provided by
Tom Schmit and Vincent Wang Rush University. All samples
were obtained under the appropriate institutional scientific review
boards from the home institutions donating tissues.
Initial tissue preparation
Lamprey notochord was extracted from and prepared from
dissected lamprey as described previously. Bovine articular
cartilage supports scraped from articular surface. Human articular
cartilage plugs were harvested from donor tissues. All tissues have
been stored in TBS* at 4uC at pH=7–7.5.
Antibody treatment for TEM and X-ray diffraction
Polyclonal biglycan antibody (Novus, epitope: DRLAIQFG-
NYKK) with 0.5 mg/ml concentration has been stored in 0.5 ml
vials at 4uC. Thin pieces of cartilage/notochord were incubated in
antibody solution for 1, 2, and 24 hours. Samples were washed in
TBS 2 times for 5 min and stored in TBS pH=7.0 at 4uC. The
specificity of the antibody was previously verified by Chen et al.,
[39]. The solution that the tissue was incubated in the presence of
antibody was collected for analysis (see SI methods S1). AFM and
TEM images were recorded for intact non-antibody treated type II
fibrils from lamprey notochord and bovine articular cartilage,
decomposed type II fibrils from both tissues and incubating
solution. Additionally microscopy data was collected from type I
collagen fibrils extracted from rat tail tendon with gold conjucated
antibody (and native untreated fibrils) as control data.
Methods are continued in SI Methods S1.
Supporting Information
Table S1 Number of fibril/fiber species per square micron:
Number of fibrils/fibers of each type: thin fibrils, thick fibers/
fibrils; for each tissue: lamprey notochord, bovine cartilage and
human cartilage; in each condition: native (control) and ab treated.
The counts are averaged to 1 square micron of area.
(DOC)
Table S2 Size of fibril/fiber species: Average diameter of fibrils/
fibers of each class for each tissue type (see methods), measured in
nm. Note that the presence of large fibril-bundles inflates the
determined average size for ‘thick-fibrils’.
(DOC)
Table S3 Results for sircol protocol (see SI Methods S1).
(DOC)




Figure 5. AFM and TEM images native and Ab treated rat tail tendon and lamprey notochord treated samples. A) Control AFM data of
type I collagen fibrils: native type I fibrils. B) Control AFM data of type I collagen fibrils: Anti- PG core protein antibody conjugated with 30 nm
particles attached to type I fibrils. Note that the fibrils are intact and that the gold particles are clearly discernible as densely packed globules. C) AFM
image of native lamprey type II fibrils. D) AFM image of lamprey type II fibrils after treatment with gold particle conjugated anti- biglycan antibodies
as in B. Compare with B. No gold particles are visible, whilst in the type I collagen control, they are clearly imaged. E) Unstained TEM of lamprey
derived collagen fibrils following anti-biglycan treatment. The antibodies in this preparation were conjugated to 10 nm gold particles and were still
able to decompose the thick fibrils into thin-fibrils, but no gold particles are visible after the preparation is washed in TBS. F) Unstained TEM of
biglycan aggregates attached to gold particle conjugated antibodies. Gold particles are clearly visible as dense black spots that do not appear in E.
doi:10.1371/journal.pone.0032241.g005
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